[1] Jan H,Christoph B,Berssenbrügge C,et al.Hepatorenal syndrome: outcome of response to therapy and predictors of survival.Gastroenterol Res Pract,2015,2015:1-8. [2] Wong F.Recent advances in our understanding of hepatorenal syndrome.Nat Rev Gastroenterol Hepatol,2012,9:382-391. [3] Modi RM,Patel N,Metwally SN,et al.Outcomes of liver transplantation in patients with hepatorenal syndrome.World J Hepatol,2016,8:999-1011. [4] Angeli P,Ginès P,Wong F,et al.Corrigendum to diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the international club of ascites.J Hepatol,2015,62:968-974. [5] Kok B,Abraldes JG. Child-Pugh classification: time to abandon? Semin Liver Dis,2019,39:96-103. [6] Hadjihambi A,Arias N,Sheikh M,et al.Hepatic encephalopathy: a critical current review.Hepatol Int,2018,12:135-147. [7] Enescu A,Petrescu F,Mitru? P,et al.Hepatorenal syndrome: diagnosis and treatment - newsreel.Rom J Intern Med,2016,54:143-150. [8] 中华医学会肝病学分会.肝硬化腹水及相关并发症的诊疗指南.实用肝脏病杂志,2018,21:21-31. [9] Bhuvanakrishna T,Blake GM,Hilton R,et al.Comparison of estimated GFR and measured GFR in prospective living kidney donors.Int Urol Nephrol,2015,47:201-208. [10] 陈盛鹏,何卫平,胡瑾华,等.肝肾综合征329例预后分析.传染病信息,2010,23:87-89. [11] Fagundes C, Ginès P. Hepatorenal syndrome: a severe, but treatable, cause of kidney failure in cirrhosis.Am J Kidney Dis,2012,59:0-0. [12] Angeli P,Guarda S,Fasolato S,et al.Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost.Aliment Pharmacol Ther,2010,23:75-84. [13] Fernández J,Navasa M,Planas R,et al.Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.Gastroenterology,2007,133:818-824. [14] Singal AK,Kamath PS.Model for end-stage liver disease.Clin Exp Hepatol,2013,3:50-60. [15] Schepke M, Appenrodt B, Jörg Heller, et al. Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD: results of a prospective study. Liver Int, 2006, 26:834-839. [16] 陆伦根. 肝性脑病:离我们并不遥远.中华消化杂志, 2017,37:508-512. [17] Aldridge DR,Tranah EJ,Shawcross DL.Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation. J Clin Exp Hepatol, 2015,5:S7-S20. [18] Møller S, Henriksen JH, Bendtsen F. Extrahepatic complications to cirrhosis and portal hypertension: Haemodynamic and homeostatic aspects.World J Gastroentero,2014,20:15499-15517. [19] Yan Y,Mai L,Zhang Y,et al.Prognostic analysis and establishment of a prognostic model for patients with liver failure with hepatorenal syndrome.Chin J Exp Clin Virol,2012,26:127-129. |